Clinical Trial Failure Risk: The company's drug candidates may fail to demonstrate safety and efficacy in clinical trials, or may experience unexpected side effects, halting their development.

Regulatory Approval Risk: Even with positive clinical trial results, CUE may be unable to obtain necessary regulatory approvals from agencies like the FDA, preventing commercialization of its product candidates.

Financing and Capital Risk: CUE is a development-stage company and will require substantial additional capital to fund its operations, clinical trials, and research, potentially leading to significant shareholder dilution.